One of the major causes of failure in chemotherapy for patients with human chronic myelogenous leukemia (CML) is the acquisition of multidrug resistance (MDR). MDR is often associated with the overexpression of drug efflux transporters of the ATP-binding cassette (ABC) protein family. Timosaponin A-III (TAIII), a saponin isolated from the rhizome of Anemarrhena asphodeloides, has previously demonstrated the ability to suppress certain human tumor processes and the potential to be developed as an anticancer agent. Nevertheless, the ability of TAIII to reverse MDR has not yet been explored. In this study, the adriamycin (ADM) resistance reversal effect of TAIII in human CML K562/ADM cells and the underlying mechanism was investigated. The Cell Counting Kit-8 (CCK-8) assay showed that TAIII had a reversal effect on the drug resistance of K562/ADM cells. Flow cytometry assay showed increased intracellular accumulation of ADM after cells were pretreated with TAIII, and the changes in the accumulation of rhodamine-123 (Rho-123) and 5(6)-carboxyfluorescein diacetate (CFDA) dye in K562/ADM cells were determined to be similar to the changes of intracellular accumulation of ADM. After pretreatment of cells with TAIII, the decreasing expression of P-gp and MRP1 mRNA was examined by reverse transcription polymerase chain reaction (RT-PCR). Western blotting showed TAIII inhibiting P-gp and MRP1 expression depended on the PI3K/Akt signaling pathway by decreasing the activity of p-Akt. Moreover, wortmannin an inhibitor of PI3K/Akt signaling pathway has a strong inhibitory effect on the expression of p-Akt, P-gp and MRP1. Besides, the combined treatment with TAIII did not have an affect on wortmannin downregulation of p-Akt, P-gp and MRP1. Taken together, our findings demonstrate, for the first time, that TAIII induced MDR reversal through inhibition of P-gp and MRP1 expression and function with regained adriamycin sensitivity which might mainly correlate to the regulation of PI3K/Akt signaling pathway.
Introduction
Chronic myeloid leukemia (CML) is a well-described hematopoietic malignancy as a result of the generation of the BCR-ABL fusion oncogene (1) . Systemic chemotherapy is the main treatment method for patients with CML. Although the majority of the CML patients respond to therapy, >62.5% of the patients will experience multidrug resistance (MDR) (2) . MDR is the main reason for tumor chemotherapeutic failure, and finding selective MDR reversal agents has become a research focus. MDR is often associated with overexpression of drug efflux transporters belonging to adenosine triphosphate (ATP)-dependent binding cassette (ABC) protein family (3) . A large number of studies revealed that multidrug resistance 1 (MDR1), also known as P-glycoprotein or ABCB1, and multidrug resistance-associated protein 1 (MRP1), also known as ABCC1, which are ABC transporters and work as drug efflux pumps, play crucial roles in MDR of human CML (2-7).
The phosphoinositide 3-kinase/serine-threonine kinase (PI3K/Akt) signaling pathway is a well-known fundamental intracellular signaling transduction pathway involved in multiple biological processes both in normal and cancer cells, including gene transcription and translation, cell growth, proliferation and survival, cell metabolism, cell cycle progression, apoptosis and autophagy (8) (9) (10) . Besides, there is an increasing amount of preclinical data supporting that the PI3K/Akt signaling pathway is also involved in the drug resistance of different types of human malignant cells, including Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway CML (2, 4, 5, (12) (13) (14) (15) . A previous study demonstrated that the resistant CML cell line K562/ADM presented higher PI3K/ Akt activity than the sensitive one and was in accordance with the MDR phenotype (2) . Moreover, there is a positive relationship between the levels of P-gp and MRP1 and the activity of PI3K/Akt signaling pathway (4) . The increasing level of p-Akt showed high activation of PI3K/Akt signaling pathway in drug-resistant CML cell lines. Blocking the PI3K/Akt signaling pathway with LY294002 (a PI3K-specific inhibitor) or Akt siRNA could downregulate the expression of P-gp and MRP1 and restore drug sensitivity (2, 4) . Although the exact mechanisms that underlie the role of PI3K/Akt signaling pathway activation remain unclear, these data clearly support that PI3K/Akt pathway plays an important role in the pathogenesis of MDR in CML. Rhizoma Anemarrhenae (Zhimu in Chinese), a wellknown traditional Chinese medicinal herb, which is officially listed in the Chinese Pharmacopoeia, has been effectively used for febrile diseases in oriental clinical practices. Timosaponin A-III (TAIII), a steroidal saponin isolated from the rhizomes of Anemarrhena asphodeloides (AA), has been credited with a wide spectrum of bioactivities, including improving learning and memory (16) , inhibiting inflammation (17) , suppressing allergic reaction (18) , controlling hyperglycemic (19, 20) , activating autophagy (21) and inducing cancer cells apoptosis (22) (23) (24) . However, the ability of TAIII to reverse MDR has not been reported. In this study, for the first time, we explored the effects of TAIII on the reversal of multidrug resistant and demonstrated its molecular mechanism.
Materials and methods
Chemicals and reagents. TAIII (purity >98%, Yuanye Bio-Technology Co. Ltd., Shanghai, China), wortmannin (a specific PI3K inhibitor, Beyotime Institute of Biotechnology, Shanghai, China), rhodamine-123 (Rho-123, Sigma Chemical Co., St. Louis, MO, USA) and 5(6)-carboxyfluorescein diacetate (CFDA, Sigma Chemical Co.) were dissolved in dimethyl sulfoxide (DMSO, Amresco, USA) at the concentrations 200 µM, 10 mM, 1 mg/ml and 1 mM respectively aliquoted and stored at -20˚C. The stock solutions of TAIII contained a final DMSO concentration of <0.1%. Adriamycin (ADM) purchased from Melone Pharmaceutical Co., Ltd. (Dalian, China) was dissolved in a concentration of 2 g/l with ddH 2 O and stored at -20˚C. Rabbit polyclonal antibodies including anti-MDR1, MRP1, total-Akt and phosphor-Akt (Ser473) were purchased from Beijing Bioss Bio-Technology Co., Ltd. (Beijing, China). Rabbit polyclonal antibodies against GADPH was obtained from Goodhere Biotechnology Co., Ltd. (Hangzhou, China).
Cell lines and cell culture. The human CML K562 cells were obtained from Key Laboratory of Tumour Molecular Biology of Binzhou Medical University (Binzhou, China) and its MDR subline K562/ADM was purchased from the Department of Pharmacology, the Institute of Hematology of Chinese Academy of Medical Sciences (Tianjin, China). The cells were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS, both from Hyclone, USA), 100 U/ml of penicillin and 0.1 mg/ml streptomycin at 37˚C in a humidified atmosphere containing 5% CO 2 . K562/ADM cells were cultured in the same medium with an additional 4 mg/l ADM. Before the experiment, K562/ADM cells were cultured in drug-free medium for 72 h. TAIII intrinsic cytotoxic activity determination in K562/ ADM cells. CCK-8 assay was also used to determine the direct cytotoxic activity of TAIII as described above. TAIII of different concentrations at 1-16 µM were added to each well for 24 h. Relative survival rate (%) of each group = absorbance of the experimental group/the absorbance of the control group x 100%. The calculated TAIII concentration at 90% survival rate was IC10. The concentrations below IC10 were selected as the experimental concentration for TAIII to reverse drug-resistance.
Multidrug resistance determination in
Reversal efficacy of TAIII determination. Briefly, the K562/ ADM cells were seeded into a 96-well plate, then 1 or 2 µM TAIII with or without various concentrations of ADM (4-32 µg/ml) was added to each well accordingly. Then, the quantity of viable cells were determined by CCK-8 assay according to the manufacturer's instructions. ADM IC 50 was calculated using the untreated cells as the 100% viable control. The reversal fold (RF) values, as potency of reversal, were obtained from the following formula: RF=IC 50 of ADM only/ IC 50 of ADM with TAIII.
Cellular uptake of ADM. K562/ADM cells were plated in 6-well plates at a concentration of 1x10 6 cells in 1 ml growth medium. After incubation alone or with TAIII (1 and 2 µM) at 37˚C for 24 h, 3 mg/l ADM was added to designated K562/ADM cells for another 1 h at 37˚C. Then, the cells were harvested by centrifugation and washed twice with ice-cold phosphate-buffered saline (PBS). The cell-associated mean fluorescence intensity (MFI) of ADM was detected by flow cytometer using a FACSCalibur (Beckman Coulter, Brea, CA, USA) with excitation/emission wavelengths of 485/580 nm.
Rho-123 and CFDA accumulation assay. Rhodamine-123 (Rho-123) and 5(6)-carboxyfluorescein diacetate (CFDA) were, respectively, used to evaluate the transport function of P-gp and MRP1 in K562/ADM cells by flow cytometric analysis. Rho-123 was a special substrate for P-gp which contains yellow-green fluorophores. CFDA was used as a model MRP1 substrate to evaluate the function of MRP1 (25) .
A total of 6x10 5 cells were seeded into 6-well plates which were pretreated with TAIII (1 and 2 µM) for 24 h followed by combined-treatment with Rho-123 (2 µg/ml) or CFDA (1 µM) for another 30 min at 37˚C in 5% CO 2 . Cells with the equivalent amount of DMSO, without Rho-123, CFDA and TAIII were used to evaluate cell auto-fluorescence. Then, the cells were harvested and washed twice with cold PBS and subsequently analyzed by flow cytometry. The values were expressed by the mean fluorescence intensity of Rho-123 and CFDA.
RT-PCR analysis. After treatment with 1 or 2 µM TAIII for 24 h, ~3x10 6 cells were harvested for RT-PCR analysis. Total RNA was isolated from the cells using TRIzol reagent (Invitrogen, USA) according to the manufacturer's instructions. Total RNA was reverse transcribed to cDNA and stored at -20˚C. Primers were synthesized by Sangon Biotech Co., Ltd. (Shanghai, China). Primers used in RT-PCR were as follows: MDR1 forward, 5'-GGAGCCTACTTGGTGGCACATAA-3'; reverse, 5'-TGGCATAGTCAGGAGCAAATGAAC-3'. MRP1 forward, 5'-CTGGGAACATGATTAGGAAGC-3'; reverse, 5'-GAGGATTTCCCAGAGCCGAC-3'. GAPDH forward, 5'-GAAGGTGAAGGTCGGAGTC-3'; reverse, 5'-GAAGAT GGTGATGGGATTTC-3'. RT-PCR was performed on an ABI PRISM 7500 real-time PCR system (Applied Biosystems, Foster City, CA, USA) by using SYBR Green reaction kit (Takara, Bio, Otsu, Shiga, Japan). The reaction system of PCR was: SYBR green reagent, forward primer, reverse primer, template cDNA and nuclease-free distilled water. PCR programs were carried out as follows: 95˚C for 30 sec, followed by 45 cycles of 95˚C for 5 sec, 60˚C for 30 sec. GAPDH served as an internal control. The PCR products were separated by 1% agarose gels. The gels were scanned and analyzed by the Gel Imaging System. RT-PCR for each gene of each cDNA sample was assayed in triplicate.
Western blot analysis. After different treatments, the cells were harvested and washed with PBS. Lysis buffer (100 µl) (Beyotime Biotechnology) was added and the protein concentration of the lysate was determined using a Bicinchoninic Acid Protein Assay kit (Beyotime Biotechnology). The lysed samples containing 50 µg were separated by 6-10% sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE, Beyotime Biotechnology) with a constant voltage of 80 V for 0. 5 h and 120 V for another 1.5 h. The resolved proteins were electrophoretically transferred to polyvinylidine difluoride membranes (EMD Millipore, Bedford, MA, USA) and blocked with 5% skimmed milk for 2 h. Subsequently, the membranes were incubated overnight at 4˚C with specific antibodies. The primary antibodies were rabbit polyclonal antibodies against P-gp (1:500), MRP-1 (1:500), total-Akt (1:500), p-Akt (1:500), GADPH (1:1,000). The following day, the membranes were incubated in horseradish peroxidase-labeled goat anti-rabbit immunoglobulin G (1:5,000) for 2 h at room temperature. Finally, images were captured by a FluorChem FC2 gel imaging system (Alpha Innotech, San Leandro, CA, USA). The intensity of each band was normalized by GADPH for their respective lanes.
Data analysis. Statistical analyses were performed using SPSS17.0 software (IBM SPSS, Armonk, NY, USA). Data were expressed as the means ± SD. Statistical comparisons were evaluated by one-way ANOVA. Values of P<0.05 was considered statistically significant.
Results
Multi-drug resistance of K562/ADM cells. Compared with its parental cells, K562/ADM cells showed clear drug-resistant property. As shown in Table I , the IC 50 of ADM on K562 and K562/ADM cells were 1.013 and 32.176 mg/l, respectively. The drug-resistance was 31.78-fold (P<0.05).
Direct cytotoxic activity of TAIII. TAIII inhibited viability of K562/ADM cells in a dose-dependent manner (Fig. 1) . TAIII of 1 µM had no significant cytotoxicity (cell growth inhibition <5%), and 2 µM TAIII had a very weak cytotoxicity (cell growth inhibition <10%). To minimize TAIII itself on K562/ADM cells growth, 1 and 2 µM was selected.
Reversal of drug resistance by TAIII. As shown in Fig. 2 
Effect of TAIII on the intracellular accumulation of ADM.
The intracellular accumulation of ADM decreased significantly in K562/ADM cells compared to the parental K562 cells (26, 27) . We determined that TAIII increased the intracellular accumulation of ADM in K562/ADM cells. Our results indicated that TAIII elevated the sensitivity of K562/ADM cells toward ADM through increasing intracellular ADM accumulation ( Fig. 3A; P<0 .05). As show in Fig. 3D , the fluorescence intensity of ADM in TAIII-treated K562/ADM cells increased in a dose-dependent manner compared to untreated K562/ADM cells.
TAIII inhibits P-gp and MRP1-mediated transport.
To assess the impact of TAIII treatment on the function of P-gp and MRP1 as efflux pump in K562/ADM cells, we examined the P-gp-mediated Rho-123 and MRP1-mediated CFDA transports in the cells treated with TAIII. As shown in Fig. 3B , Fig. 3C and D, TAIII treatment significantly increased the intracellular accumulation of Rho-123 and CFDA in a dosedependent manner (P<0.05).
TAIII decreases expression of P-gp and MRP1 in K562/ADM cells via the PI3K/Akt signaling pathway. P-gp and MRP1
are ABC transporters, which are overexpressed in many drug-resistant cells (8, 12, 13) . K562/ADM cells express higher levels of P-gp and MRP1 than K562 cells (26, 28) . In this study, K562/ADM cells expressed P-gp and MRP1 protein at high level. After incubation alone or with TAIII (1 and 2 µM) for 24 h, the expression levels of P-gp and MRP1 were determined by RT-PCR and western blotting (Figs. 4 and 5) . The results of RT-PCR are shown in the Fig. 4 , the MDR1 and MRP1 mRNA expression in K562/ADM cells significantly decreased in a dose-dependent manner (P<0.05). The results of western blotting are shown in Fig. 5 , compared to the negative control group, TAIII was able to induce a significant downregulation of P-gp and MRP1 protein expression in a dose-dependent manner. These results indicated that TAIII could modulate P-gp and MRP1 gene expression, thus increasing the intracellular ADM accumulation. PI3K/Akt signaling pathway played a vital role in the development of CML MDR, and was closely related to high expressions of P-gp and MRP1 (2, 4) . In order to further analyze the inhibitory effects of TAIII on the expression of P-gp and MRP1, we analyzed the alteration of total expression and activity of Akt (Akt Ser473) in K562/ADM cells. Akt is one of the most important modulators in PI3K/Akt pathway. As shown in Fig. 5 , after treatment with TAIII for 24 h, the expression of total-Akt did not change apparently, whereas the expression of Akt phosphorylation (Akt Ser473) changed significantly (P<0.05, Fig. 5 ). These data suggested that the PI3K/Akt pathway is involved in the TAIII mediated reversal of multidrug resistance of K562/ADM cells. Blocking PI3K/Akt pathway modulates the chemosensitivity of K562/ADM cells. To further determine the causal relationship between chemosensitivity and TAIII-inactivated PI3K/ Akt signaling pathway on cell MDR, specific inhibitor of PI3K/Akt wortmannin was selected to treat K562/ADM cells which overexpressed P-gp and MRP1. The protein levels of total-Akt, Akt Ser473, P-gp and MRP1 were measured. As shown in Fig. 6 , K562/ADM cells with the inhibitor wortmannin treatment showed significantly decreasing protein levels of Akt Ser473, P-gp and MRP1, whereas total Akt was not affected by inhibition (P<0.05).
The inhibition of PI3K/Akt pathway plays a crucial role in the multidrug-resistance reversal of TAIII. In order to confirm the role of PI3K/Akt signaling pathway in TAIII-mediated reversal effect of multidrug resistance, we analyzed the proteins level of total-Akt, Akt Ser473, P-gp and MRP1 in K562/ADM cells by western blotting. The cells were treated with wortmannin (1 µM) alone and combined-treatment with TAIII (1 and 2 µM) for 24 h. The results of western blotting are shown in Fig. 7 , compared with wortmannin (1 µM) alone group, wortmannin (1 µM) combined with TAIII (1 µM) group and wortmannin (1 µM) combined with TAIII (2 µM) group did not attenuate the expression of p-Akt, P-gp and MRP1. Since TAIII did not strengthen the inhibitor function, we may conclude that PI3K/ Akt signaling pathway was mainly responsible for the drug resistance reversal effect of TAIII.
Discussion
CML is one of the most genetically homogeneous malignancies characterized by clonal myeloid cells with an abnormal fusion protein, BCR-ABL, which has tyrosine kinase activity.
Since biological sample collection is a non-invasive process, CML is one of the extensively studied diseases for gene expression profiling, which needs elucidation of the BCR-ABL downstream mechanisms involved in CML progression and the pathways involved in therapy resistance. Although the BCR-ABL-targeting tyrosine kinase inhibitors (TKIs) has shown significant progress toward treatment against CML, the drug did not successfully cure patients of the disease (9, 29) . MDR has become a main obstacle for chemotherapy of CML. Mechanism of MDR is associated with altered expression of ATP-binding cassette (ABC) family of transporters on cell membrane, the most common cause of multidrug resistance (MDR) (1) . While as many as 18 ABC transporters have been observed to export chemotherapy drugs using in vitro experimental systems, only 3 transporters have been implicated as major contributors to MDR in cancer: P-glycoprotein (Pgp; ABCB1; MDR1), multidrug resistance-associated protein (MRP1; ABCC1) and breast cancer resistance protein (BCRP; ABCG) (30) . Moreover, among the three transporters, the expression of P-gp and MRP1 was extensively measured, studied in CML and its expression levels were correlated with multidrug resistance (31) .
The PI3K/Akt signaling pathway has become an important player in the pathogenesis of MDR CML and a promising target for systemic therapy (1,2,4,5,9-11). Many cancer cells have mutations in the PI3K/Akt pathway that leads to hyperactivation of this pathway. In previous studies, it was reported that the PI3K/Akt signaling pathway was always prominently activated by many regulators and was strongly linked to prosurvival in cancer cells (9) . Moreover, several lines of evidence implicated that the activating of PI3K/Akt signaling pathway had enhanced drug efflux by ATP-binding cassette (ABC) transporters (2) . The maintaining of MDR in tumor cells by PI3K/Akt signaling pathway was most correlated with P-gp and MRP1 (4) . Blocking the PI3K/Akt signaling pathway results in the downregulation of the expression of P-gp and MRP1, the sensitivity to chemotherapy drugs was regained (4) . TAIII, one of the main active constituents of Chinese medicinal herb Anemarrhena asphodeloides Bunge, was reported to possess a variety of pharmacological functions. There is accumulating evidence that TAIII is a pronounced activator of autophagy (21, 32, 33) . Preclinical study reported that TAIII was efficacious in inducing autophagy in various cancer cells correlating with a potent inhibitory effect on the activity of mammalian target of rapamycin (mTOR) (31) (32) (33) . Moreover, it has been reported that the PI3K/Akt/mTOR signaling pathway played a suppressive role in autophagy (10) . Furthermore, TAIII can also induce tumor cells apoptosis by inhibition of mTORC1 (34) . Nuclear factor-kappa B (NF-κB) is a transcription factor universally present in eukaryocytes, and it can enter into the nucleus and bind to some specific κB sequences thus inducing or upregulating expression of certain genes (27) . Previous studies demonstrated that NF-κB could bind to the specific κB sequences on the first exon of the MDR1 promoter region and then upregulated the expression of P-gp to induce drug resistance (27, 35) . Studies have shown that TAIII has strong anti-inflammatory properties by inhibiting the expression of inflammatory cytokines via inhibition of NF-κB activation (16, 17) . However, NF-κB was also reported as a downstream signal molecule of PI3K/Akt signaling pathway (36, 37) . Based on these studies, it is possible to conclude that TAIII may have an inhibition effect on PI3K/ Akt signaling pathway.
In this study, we investigated the effects of MDR reversal in a CML multidrug-resistant cell line K562/ADM using TAIII. Firstly, we determined the non-toxic concentration of TAIII to reverse drug-resistance. We found that TAIII of 1 and 2 µM showed very weak cytotoxcity (cell growth inhibition <10%). Then, our data demonstrated that TAIII and ADM combined treatment sensitized K562/ADM cells and induced apoptosis in a dose-dependent manner, decreasing P-gp and MRP1 gene expression. Additionally, the combined treatment reduced the expression of phosphorylated Akt (p-Akt) without affecting the expression of total-Akt, that means the activity of PI3K/ Akt signaling pathway was downregulated. Moreover, we found that the levels of p-Akt, P-gp and MRP1 in K562/ADM cells decreased after exposure to the specific inhibitor of PI3K/ Akt wortmannin. However, TAIII treatment combined with wortmannin did not exhibit strengthen effect on downregulation of P-gp and MRP1 expression. Therefore, it is reasonable to believe that TAIII plays a suppressive role in the expression of P-gp and MRP1 via inhibition of the PI3K/Akt signaling pathway.
The above studies show that TAIII could increase the intracellular accumulation of ADM in K562/ADM cells at non-toxic concentrations by downregulating P-gp and MRP1 expressions, function and transcription via a mechanism involving the inhibition of the PI3K/Akt signaling pathway. The studies provide evidence in support of further investigation into the clinical application of TAIII as new, potent, and clinically relevant MDR reversal agent in cancer chemotherapy.
